Experimed Bioscence Inc discovers and develops novel human antibody therapeutics as treatments for infectious disease and oncology indications. The company leverages its proprietary platform technology, to find rare human antibodies with superior selectivity, affinity and other drug parameters. The company is building a pipeline of monoclonal antibodies in early stage development.
